Prosecution Insights
Last updated: April 19, 2026
Application No. 18/718,087

GUIDEWIRE AND CATHETER SELECTION AND REAL-TIME GUIDANCE

Final Rejection §102
Filed
Jun 10, 2024
Examiner
LUONG, PETER
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Koninklijke Philips N V
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
3y 10m
To Grant
96%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
501 granted / 727 resolved
-1.1% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
29 currently pending
Career history
756
Total Applications
across all art units

Statute-Specific Performance

§101
7.4%
-32.6% vs TC avg
§103
38.9%
-1.1% vs TC avg
§102
22.9%
-17.1% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 727 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-20 are is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhao et al. (US 2014/0187949). With respect to claims 1, 7, 15 and 19, Zhao et al. discloses a vascular therapy apparatus comprising: an electronic processing device ([0028]) comprising at least one electronic processor programmed to: retrieve an intravascular instrument model of an associated intravascular instrument to be used in an intravascular procedure ([0060]); retrieve a patient model of anatomy including at least vasculature of a patient who is to undergo the intravascular procedure ([0050]); and before and/during the intravascular procedure, model a passage of the associated intravascular instrument through vasculature of the associated patient using the instrument model and the patient model ([0052]); and output treatment information for the intravascular therapy procedure based on the modeled passage of the associated intravascular instrument through the vasculature of the associated patient, wherein the modeling of the passage of the associated intravascular instrument through the vasculature of the associated patient includes: modeling friction force on the associated intravascular instrument as a function of position along the associated intravascular instrument during the passage of the associated intravascular instrument through the vasculature ([0054-0055]). Zhao et al. discloses modeling tissue damage risk ([0053]; [0055-0056]; [0058-0059]). With respect to claims 2 and 16, Zhao et al. discloses a plurality of difference candidate routes including a recommended route ([0057]). With respect to claims 3 and 17, Zhao et al. discloses a plurality of different candidate associated instruments ([0048]; [0060]; [0062]). With respect to claim 4, Zhao et al. discloses identification of regions of high friction force on the instrument ([0054]; [0060]). With respect to claims 5 and 8, Zhao et al. discloses a visual rendering ([0031-0032]; [0050]; [0057]). With respect to claims 6 and 18, Zhao et al. discloses sensors ([0037-0038]). With respect to claims 9 and 20, Zhao et al. discloses receiving medical images ([0028]; [0031]). With respect to claim 10, Zhao et al. discloses treatment information ([0055-0056]; [0062]). With respect to claim 11, Zhao et al. discloses using the models to perform scenarios ([00062-0063]). With respect to claim 12, Zhao et al. discloses diameter and stiffness ([0054]). With respect to claim 13, Zhao et al. discloses geometrical layout ([0055]; [0066]; [0076]) and tissue information ([0058]; [0061]). With respect to claim 14, Zhao et al. discloses a generic patient model or a patient specific model ([0050]). Response to Arguments Applicant's arguments filed 9/17/2025 have been fully considered but they are not persuasive. Applicant's arguments fail to comply with 37 CFR 1.111(b) because they amount to a general allegation that the claims define a patentable invention without specifically pointing out how the language of the claims patentably distinguishes them from the references. Applicant argues the reference does not teach modeling friction force. However, the Examiner respectfully disagrees with the applicant. The Examiner’s position is that Zhao et al. discloses modeling friction force ([0054-0055]). Zhao et al. discloses many factors (factors which are interpreted to cause friction) about operational capability including bending capability, flexibility and elasticity, shape characteristics, steerability, diameter of catheter, diameter of tool, trajectory of tool, movement of the too including sweeping and spinning, angulation, and frictional contact ([0054-0055]). Applicant argues the reference does not teach modeling tissue damage risk. However, the Examiner respectfully disagrees with the applicant. Zhao et al. discloses minimizing risk of tissue damage ([0053]). Zhao et al. discloses selecting deployment location that reduces risk to surrounding tissue ([0055-0056]). Zhao et al. discloses risk associated with contacting the surrounding tissue ([0058]). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PETER LUONG whose telephone number is (571)270-1609. The examiner can normally be reached M-F 9-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anhtuan T Nguyen can be reached at (571)272-4963. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PETER LUONG/Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

Jun 10, 2024
Application Filed
Jun 14, 2025
Non-Final Rejection — §102
Sep 17, 2025
Response Filed
Jan 10, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12602772
SYSTEMS AND METHODS FOR RAPID NEURAL NETWORK-BASED IMAGE SEGMENTATION AND RADIOPHARMACEUTICAL UPTAKE DETERMINATION
2y 5m to grant Granted Apr 14, 2026
Patent 12599368
INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND PROGRAM
2y 5m to grant Granted Apr 14, 2026
Patent 12582383
ULTRASOUND IMAGE PROCESSING METHOD, AND ULTRASOUND APPARATUS USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12551124
SYSTEMS AND METHODS FOR MEASURING CAPILLARY REFILL TIME
2y 5m to grant Granted Feb 17, 2026
Patent 12544153
INDWELLING-TYPE MEDICAL DEVICE AND ENDOSCOPE SYSTEM USING THE SAME
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
96%
With Interview (+26.9%)
3y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 727 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month